← 產業報告目錄

Biopharmaceutical Contract Manufacturing Market by Service (Manufacturing, Fill-Finish), Type (Drug Substance, Drug Product), Scale (Clinical), Source (Mammalian), Therapy Area (Oncology), Molecule Type (mAbs, ADC, CGT, Vaccines) - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-08-06頁數 383報告編號 BT8780

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global biopharmaceutical contract manufacturing market is expected to reach USD 34.15 billion by 2030 from an estimated USD 22.40 billion in 2025, at a CAGR of 8.8% from 2025 to 2030. This growth in the biopharmaceutical contract manufacturing market is primarily driven by advancements in manufacturing technologies and a growing emphasis on personalized medicine. However, evolving regulations may pose challenges that could limit market expansion. The monoclonal antibodies segment accounted for the largest share of the biopharmaceutical contract manufacturing market in 2024. The biopharmaceutical contract manufacturing market is segmented by molecule type into monoclonal antibodies (mAbs), cell & gene therapy, antibody-drug conjugates, vaccines, therapeutic peptides & proteins, and other molecules. The mAbs segment leads the market due to the rising prevalence of chronic disorders like cancer and autoimmune diseases, driving the demand for targeted therapies. Monoclonal antibodies are preferred in clinical practice for their precision in targeting specific disease pathways. Government support for mAb research has encouraged biopharmaceutical firms to expand their pipelines, increasing the number of mAb candidates in clinical trials. Consequently, contract manufacturing organizations are experiencing a growing demand for their services to produce these advanced biologics efficiently and cost-effectively. The mammalian expression systems segment dominated the market in 2024. The mammalian expression systems segment dominates the global biopharmaceutical contract manufacturing market, primarily due to its critical role in creating complex biologics like monoclonal antibodies. This dominance stems from the ability of mammalian cell platforms to perform intricate post-translational modifications, enhancing treatment effectiveness. The rising demand for advanced biologics and increased investments in cell culture technologies have further solidified this segment. Contract manufacturing organizations are expanding their mammalian cell culture capabilities and adopting advanced technologies to improve yield and quality. As the pipeline for biologics grows, the mammalian expression systems segment is expected to continue driving growth and innovation in biopharmaceutical manufacturing. Europe accounted for the second-largest share of the market from 2025 to 2030. The biopharmaceutical contract manufacturing market in Europe is the second largest during the forecast period, driven by rising investments in biologics such as monoclonal antibodies and cell & gene therapies, along with expansions in biomanufacturing capacity. The region is a hub for innovation, focusing on advanced technologies that enhance quality and efficiency. For example, in March 2023, Lonza launched a cGMP manufacturing site for large-scale drug production, underscoring Europe’s commitment to meeting the global demand for complex biologics and attracting pharmaceutical and biotech firms seeking top-tier contract manufacturing services. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Supply Side (70%) and Demand Side (30%) • By Designation: Managers (45%), CXOs and Directors (30%), and Executives (25%) • By Region: North America (40%), Europe (25%), the Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%) List of Key Companies Profiled in the Report: Key players in the biopharmaceutical contract manufacturing market include Lonza (Switzerland), Thermo Fisher Scientific Inc. (US), WuXi Biologics (China), Catalent, Inc. (US), Samsung Biologics (South Korea), Boehringer Ingelheim International GmbH (Germany), FUJIFILM Holdings Corporation (Japan), AbbVie, Inc. (US), Eurofins Scientific (Luxembourg), GenScript Biotech Corporation (US), AGC Inc. (Japan), Merck KGaA (Germany), JSR Corporation (Japan), IDT Biologika (Germany), Ajinomoto Bio-Pharma (Japan), Agilent Technologies, Inc. (US), and Asahi Kasei Corporation (Japan). Research Coverage: This research report categorizes the biopharmaceutical contract manufacturing market by service (manufacturing, formulation & fill-finish, packaging & labeling, and other services), type (biologic drug substance manufacturing and biologic drug product manufacturing), scale of operation (clinical and commercial operations), source (mammalian and non-mammalian expression systems), therapeutic area (oncology, autoimmune diseases, metabolic diseases, cardiovascular diseases, neurology, infectious diseases, and other therapeutic areas), molecule type (monoclonal antibodies, antibody-drug conjugates, cell & gene therapy, vaccines, therapeutic peptides & proteins, and other molecules), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa). The report provides a comprehensive analysis of the key factors affecting the growth of the biopharmaceutical contract manufacturing market, including drivers, restraints, challenges, and opportunities. It includes an in-depth examination of major industry players, offering insights into their business overviews, products, solutions, and key strategies, as well as their collaborations, partnerships, and agreements. Additionally, the report highlights recent developments related to new approvals and launches, mergers and acquisitions, and other significant activities in the biopharmaceutical contract manufacturing market. Key Benefits of Buying the Report: The report will assist both market leaders and new entrants by providing accurate revenue estimates for the overall biopharmaceutical contract manufacturing market and its subsegments. It will also help stakeholders better understand the competitive landscape, enabling them to better position their businesses and develop effective go-to-market strategies. Additionally, this report will offer insights into the market's dynamics, including key drivers, constraints, opportunities, and challenges. The report provides insights on the following pointers: • Analysis of key drivers (rising demand for outsourcing services, increasing demand for biologics & biosimilars, increased focus on personalized medicine, industrial collaborations for drug discovery and development/strategic partnerships and collaborations, and advancements in manufacturing technologies), restraints (challenges complying with regulatory reforms), opportunities (rising demand for cell & gene therapy, emerging countries market, and strong emphasis on drug development), and challenges (challenges to meet reformed regulations) influencing the growth of the market. • Service Development/Innovation: Detailed insights on the upcoming technologies and research & development activities in the biopharmaceutical contract manufacturing market. • Market Development: The report provides comprehensive information about profitable markets by analyzing them across various regions. • Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the biopharmaceutical contract manufacturing market. • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, service launches/approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the biopharmaceutical contract manufacturing market.
目錄 Table of Contents
1 INTRODUCTION 34 1.1 STUDY OBJECTIVES 34 1.2 MARKET DEFINITION 34 1.3 STUDY SCOPE 35 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 35 1.3.2 INCLUSIONS & EXCLUSIONS 36 1.3.3 YEARS CONSIDERED 37 1.4 CURRENCY CONSIDERED 37 1.5 STAKEHOLDERS 37 1.6 SUMMARY OF CHANGES 38 2 RESEARCH METHODOLOGY 39 2.1 RESEARCH DATA 39 2.1.1 SECONDARY DATA 40 2.1.1.1 Objectives of secondary research 40 2.1.1.2 Key data from secondary sources 41 2.1.2 PRIMARY DATA 41 2.1.2.1 Breakdown of primaries (supply- and demand-side participants) 42 2.1.2.2 Key objective of primary research 42 2.2 MARKET ESTIMATION 43 2.2.1 GLOBAL MARKET ESTIMATION 43 2.2.1.1 Company revenue analysis (bottom-up approach) 43 2.2.1.1.1 Revenue share analysis of Thermo Fisher Scientific Inc. 44 2.2.1.2 MnM repository analysis 45 2.2.1.3 Primary interviews 46 2.2.2 INSIGHTS OF PRIMARY EXPERTS 46 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH) 47 2.3 MARKET GROWTH RATE PROJECTIONS 48 2.4 DATA TRIANGULATION 49 2.5 STUDY ASSUMPTIONS 50 2.6 RESEARCH LIMITATIONS 51 2.7 RISK ANALYSIS 51 3 EXECUTIVE SUMMARY 52   4 PREMIUM INSIGHTS 56 4.1 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET OVERVIEW 56 4.2 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION AND COUNTRY (2025) 57 4.3 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY THERAPEUTIC AREA, 2025 VS. 2030 57 4.4 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2025 VS. 2030 (USD MILLION) 58 4.5 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59 5 MARKET OVERVIEW 60 5.1 INTRODUCTION 60 5.2 MARKET DYNAMICS 60 5.2.1 DRIVERS 61 5.2.1.1 Increasing outsourcing of biologics manufacturing among biopharmaceutical companies 61 5.2.1.2 Rising demand for biologics and biosimilars 62 5.2.1.3 Growing focus on personalized medicine 64 5.2.1.4 Increasing collaborations between pharmaceutical companies and biologics CMOs 65 5.2.1.5 Advancements in manufacturing technologies 66 5.2.2 RESTRAINTS 66 5.2.2.1 Intellectual property rights issues 66 5.2.3 OPPORTUNITIES 67 5.2.3.1 Rising demand for cell & gene therapy 67 5.2.3.2 Significant growth opportunities offered by emerging countries 68 5.2.3.3 Expansion of biologics manufacturing capacities by CMOs 68 5.2.4 CHALLENGES 69 5.2.4.1 Strict regulations 69 5.3 TECHNOLOGY ANALYSIS 70 5.3.1 KEY TECHNOLOGIES 70 5.3.1.1 Single-use technologies 70 5.3.1.2 Continuous bioprocessing 70 5.3.2 COMPLEMENTARY TECHNOLOGIES 70 5.3.2.1 Robotics and automation in fill-finish 70 5.3.2.2 CRISPR & gene editing tools 71 5.3.3 ADJACENT TECHNOLOGIES 71 5.3.3.1 3D bioprinting & microfluidics 71 5.3.3.2 Biosensors & real-time analytics 71 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 72 5.5 PRICING ANALYSIS (QUALITATIVE) 73 5.6 VALUE CHAIN ANALYSIS 74 5.7 ECOSYSTEM ANALYSIS 75 5.8 PATENT ANALYSIS 77 5.9 REGULATORY ANALYSIS 79 5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79 5.9.2 REGULATORY LANDSCAPE 82 5.10 KEY CONFERENCES & EVENTS, 2025–2026 85 5.11 PORTER’S FIVE FORCES ANALYSIS 86 5.11.1 THREAT OF NEW ENTRANTS 87 5.11.2 THREAT OF SUBSTITUTES 87 5.11.3 BARGAINING POWER OF SUPPLIERS 87 5.11.4 BARGAINING POWER OF BUYERS 87 5.11.5 INTENSITY OF COMPETITIVE RIVALRY 87 5.12 KEY STAKEHOLDERS & BUYING CRITERIA 88 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 88 5.12.2 BUYING CRITERIA 89 5.13 INVESTMENT & FUNDING SCENARIO 90 5.14 IMPACT OF AI/GEN AI ON BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET 91 5.15 IMPACT OF 2025 US TARIFFS ON BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET 92 5.15.1 INTRODUCTION 92 5.15.2 KEY TARIFF RATES 93 5.15.3 PRICE IMPACT ANALYSIS 94 5.15.4 IMPACT ON COUNTRY/REGION 95 5.15.4.1 US 95 5.15.4.2 Europe 95 5.15.4.3 APAC 96 5.15.5 IMPACT ON UPSTREAM INDUSTRIES 96 6 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE 97 6.1 INTRODUCTION 98 6.2 MANUFACTURING 98 6.2.1 SHIFT TOWARD CONTINUOUSLY IMPROVING SINGLE-USE TECHNOLOGIES TO DRIVE MARKET 98 6.3 FORMULATION & FILL-FINISH 102 6.3.1 CRITICAL ROLE OF FORMULATION & FILL-FINISH IN BIOLOGICS MANUFACTURING TO DRIVE MARKET GROWTH 102 6.4 PACKAGING & LABELING 105 6.4.1 IMPORTANCE OF PACKAGING & LABELING IN ENSURING SAFETY AND EFFECTIVENESS TO SUPPORT MARKET GROWTH 105 6.5 OTHER SERVICES 108   7 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE 112 7.1 INTRODUCTION 113 7.2 BIOLOGIC DRUG SUBSTANCE MANUFACTURING 113 7.2.1 INCREASING DEMAND FOR BIOTECHNOLOGY PRODUCTS TO DRIVE MARKET 113 7.3 BIOLOGIC DRUG PRODUCT MANUFACTURING 117 7.3.1 INCREASING R&D COST AND PROCESS COMPLEXITY TO DRIVE DEMAND FOR CONTRACT MANUFACTURING FOR BIOLOGIC DRUG PRODUCTS 117 8 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION 121 8.1 INTRODUCTION 122 8.2 COMMERCIAL OPERATIONS 122 8.2.1 INCREASING APPROVALS OF BIOLOGICS TO SUPPORT MARKET GROWTH 122 8.3 CLINICAL OPERATIONS 126 8.3.1 INCREASING NUMBER OF CLINICAL TRIALS FOR TARGETED THERAPIES TO DRIVE MARKET 126 9 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE 130 9.1 INTRODUCTION 131 9.2 MAMMALIAN EXPRESSION SYSTEMS 131 9.2.1 VERSATILE THERAPEUTIC DIVERSITY OF MAMMALIAN EXPRESSION SYSTEMS TO DRIVE MARKET 131 9.3 NON-MAMMALIAN EXPRESSION SYSTEMS 135 9.3.1 INCREASING DEMAND FOR BIOLOGICS VACCINES TO SUPPORT MARKET GROWTH 135 10 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE 140 10.1 INTRODUCTION 141 10.2 MONOCLONAL ANTIBODIES 141 10.2.1 GROWING APPROVALS FOR MABS TO PROPEL MARKET 141 10.3 CELL & GENE THERAPY 144 10.3.1 INCREASING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET 144 10.4 ANTIBODY-DRUG CONJUGATES 148 10.4.1 INCREASING INVESTMENTS IN BIOLOGICS TO SUPPORT MARKET GROWTH 148 10.5 VACCINES 151 10.5.1 INCREASING DEMAND FOR VACCINES TO DRIVE MARKET 151 10.6 THERAPEUTIC PEPTIDES & PROTEINS 155 10.6.1 INCREASING NUMBER OF RESEARCH PROJECTS IN GENOMICS TO SUPPORT MARKET GROWTH 155 10.7 OTHER MOLECULES 159 11 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA 163 11.1 INTRODUCTION 164 11.2 ONCOLOGY 164 11.2.1 INCREASED APPROVALS AND LAUNCH OF BIOLOGICS FOR ONCOLOGY TO DRIVE MARKET 164 11.3 AUTOIMMUNE DISEASES 168 11.3.1 RISING PREVALENCE OF AUTOIMMUNE DISEASES TO DRIVE MARKET 168 11.4 CARDIOVASCULAR DISEASES 171 11.4.1 DEVELOPMENT OF NEW TREATMENT OPTIONS TO SUPPORT MARKET GROWTH 171 11.5 METABOLIC DISEASES 174 11.5.1 INCREASING PREVALENCE OF METABOLIC DISEASES TO DRIVE ADOPTION OF BIOLOGICS 174 11.6 INFECTIOUS DISEASES 178 11.6.1 RISING EPIDEMIC OUTBREAKS TO SUPPORT MARKET GROWTH 178 11.7 NEUROLOGY 181 11.7.1 HIGH BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET 181 11.8 OTHER THERAPEUTIC AREAS 184 12 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION 188 12.1 INTRODUCTION 189 12.2 NORTH AMERICA 189 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 190 12.2.2 US 196 12.2.2.1 Presence of large number of FDA-approved manufacturing facilities to favor market growth 196 12.2.3 CANADA 199 12.2.3.1 Rising government funding for drug development to support market growth 199 12.3 EUROPE 202 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 202 12.3.2 GERMANY 207 12.3.2.1 Rapidly growing pharmaceutical market to drive market 207 12.3.3 UK 210 12.3.3.1 Rising investments in drug development to favor market growth 210 12.3.4 FRANCE 213 12.3.4.1 Availability of funds from government and private organizations for domestic drug development to support market growth 213 12.3.5 ITALY 216 12.3.5.1 Rising commercial drug development pipeline to drive market 216 12.3.6 SPAIN 219 12.3.6.1 Rising R&D expenditure to propel market 219 12.3.7 SWITZERLAND 222 12.3.7.1 Strong R&D investments and infrastructure expansion to bolster biotech manufacturing 222 12.3.8 IRELAND 225 12.3.8.1 Robust R&D growth and CDMO capacity expansion to fuel pharma manufacturing 225 12.3.9 REST OF EUROPE 228 12.4 ASIA PACIFIC 231 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 231 12.4.2 CHINA 237 12.4.2.1 Low manufacturing cost and high demand for medicines to favor market growth 237 12.4.3 JAPAN 241 12.4.3.1 Growing demand for biosimilars to drive growth 241 12.4.4 INDIA 244 12.4.4.1 Increasing pharma R&D activities and government funding for biotechnology industry to support market growth 244 12.4.5 SOUTH KOREA 247 12.4.5.1 Increasing R&D activities for drug development to drive market 247 12.4.6 REST OF ASIA PACIFIC 250 12.5 LATIN AMERICA 253 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 253 12.5.2 BRAZIL 258 12.5.2.1 Growing pharmaceutical industry to drive market 258 12.5.3 MEXICO 261 12.5.3.1 Regulatory Improvements to support market growth 261 12.5.4 REST OF LATIN AMERICA 264 12.6 MIDDLE EAST 267 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 267 12.6.2 GCC COUNTRIES 271 12.6.2.1 Substantial opportunities fueled by strong government support to boost growth 271 12.6.3 REST OF MIDDLE EAST 274 12.7 AFRICA 278 12.7.1 EFFORTS TO IMPROVE LOCAL PHARMACEUTICAL PRODUCTION TO BOOST MARKET 278 12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 278 13 COMPETITIVE LANDSCAPE 283 13.1 OVERVIEW 283 13.2 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2022−2025 283 13.3 REVENUE ANALYSIS, 2020–2024 285 13.4 MARKET SHARE ANALYSIS, 2024 286 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 289 13.5.1 STARS 289 13.5.2 EMERGING LEADERS 289 13.5.3 PERVASIVE PLAYERS 289 13.5.4 PARTICIPANTS 289 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 291 13.5.5.1 Company footprint 291 13.5.5.2 Region footprint 292 13.5.5.3 Service type footprint 293 13.5.5.4 Molecule type footprint 294 13.5.5.5 Therapeutic area footprint 295 13.6 COMPANY EVALUATION MATRIX: SMES/STARTUPS, 2024 296 13.6.1 PROGRESSIVE COMPANIES 296 13.6.2 RESPONSIVE COMPANIES 296 13.6.3 DYNAMIC COMPANIES 296 13.6.4 STARTING BLOCKS 296 13.6.5 COMPETITIVE BENCHMARKING: SMES/STARTUPS, 2024 298 13.6.5.1 Detailed list of key SMEs/startups 298 13.6.5.2 Competitive benchmarking of key emerging players/startups 299 13.7 COMPANY VALUATION & FINANCIAL METRICS 300 13.7.1 FINANCIAL METRICS 300 13.7.2 COMPANY VALUATION 300 13.8 BRAND/PRODUCT COMPARISON 301 13.9 COMPETITIVE SCENARIO 302 13.9.1 SERVICE LAUNCHES 302 13.9.2 DEALS 302 13.9.3 EXPANSIONS 303 14 COMPANY PROFILES 304 14.1 KEY PLAYERS 304 14.1.1 LONZA 304 14.1.1.1 Business overview 304 14.1.1.2 Services offered 306 14.1.1.3 Recent developments 307 14.1.1.3.1 Deals 307 14.1.1.3.2 Expansions 308 14.1.1.4 MnM view 308 14.1.1.4.1 Key strengths 308 14.1.1.4.2 Strategic choices 308 14.1.1.4.3 Weaknesses & competitive threats 308   14.1.2 WUXI BIOLOGICS 309 14.1.2.1 Business overview 309 14.1.2.2 Services offered 311 14.1.2.3 Recent developments 312 14.1.2.3.1 Deals 312 14.1.2.3.2 Expansions 312 14.1.2.4 MnM view 313 14.1.2.4.1 Key strengths 313 14.1.2.4.2 Strategic choices 313 14.1.2.4.3 Weaknesses & competitive threats 313 14.1.3 SAMSUNG BIOLOGICS 314 14.1.3.1 Business overview 314 14.1.3.2 Services offered 316 14.1.3.3 Recent developments 316 14.1.3.3.1 Service launches 316 14.1.3.3.2 Deals 316 14.1.3.3.3 Expansions 317 14.1.3.4 MnM view 318 14.1.3.4.1 Key strengths 318 14.1.3.4.2 Strategic choices 318 14.1.3.4.3 Weaknesses & competitive threats 318 14.1.4 THERMO FISHER SCIENTIFIC INC. 319 14.1.4.1 Business overview 319 14.1.4.2 Services offered 321 14.1.4.3 Recent developments 321 14.1.4.3.1 Deals 321 14.1.4.4 MnM view 322 14.1.4.4.1 Key strengths 322 14.1.4.4.2 Strategic choices 322 14.1.4.4.3 Weaknesses & competitive threats 322 14.1.5 ABBVIE INC. 323 14.1.5.1 Business overview 323 14.1.5.2 Services offered 324 14.1.6 CATALENT, INC. 325 14.1.6.1 Business overview 325 14.1.6.2 Services offered 326 14.1.6.3 Recent developments 328 14.1.6.3.1 Deals 328 14.1.6.3.2 Expansions 328 14.1.6.4 MnM view 329 14.1.6.4.1 Key strengths 329 14.1.6.4.2 Strategic choices 329 14.1.6.4.3 Weaknesses & competitive threats 329 14.1.7 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 330 14.1.7.1 Business overview 330 14.1.7.2 Services offered 332 14.1.7.3 Recent developments 333 14.1.7.3.1 Other developments 333 14.1.8 FUJIFILM HOLDINGS CORPORATION 334 14.1.8.1 Business overview 334 14.1.8.2 Services offered 335 14.1.8.3 Recent developments 336 14.1.8.3.1 Deals 336 14.1.8.3.2 Expansions 337 14.1.9 EUROFINS SCIENTIFIC 338 14.1.9.1 Business overview 338 14.1.9.2 Services offered 340 14.1.9.3 Recent developments 340 14.1.9.3.1 Expansions 340 14.1.10 GENSCRIPT BIOTECH CORPORATION 342 14.1.10.1 Business overview 342 14.1.10.2 Services offered 344 14.1.10.3 Recent developments 344 14.1.10.3.1 Service launches 344 14.1.10.3.2 Deals 345 14.1.10.3.3 Expansions 345 14.1.11 AGC INC. 346 14.1.11.1 Business overview 346 14.1.11.2 Services offered 347 14.1.11.3 Recent developments 348 14.1.11.3.1 Deals 348 14.1.11.3.2 Expansions 349 14.1.12 MERCK KGAA 350 14.1.12.1 Business overview 350 14.1.12.2 Services offered 351 14.1.12.3 Recent developments 352 14.1.12.3.1 Deals 352 14.1.12.3.2 Expansions 352 14.1.13 JSR CORPORATION 353 14.1.13.1 Business overview 353 14.1.13.2 Services offered 355 14.1.13.3 Recent developments 355 14.1.13.3.1 Expansions 355   14.1.14 IDT BIOLOGIKA 356 14.1.14.1 Business overview 356 14.1.14.2 Services offered 356 14.1.14.3 Recent developments 357 14.1.14.3.1 Other developments 357 14.1.15 AJINOMOTO BIO-PHARMA 358 14.1.15.1 Business overview 358 14.1.15.2 Services offered 359 14.1.15.3 Recent developments 359 14.1.15.3.1 Deals 359 14.1.16 AGILENT TECHNOLOGIES INC. 360 14.1.16.1 Business overview 360 14.1.16.2 Services offered 361 14.1.16.3 Recent developments 362 14.1.16.3.1 Deals 362 14.1.17 ASAHI KASEI CORPORATION 363 14.1.17.1 Business overview 363 14.1.17.2 Services offered 364 14.1.17.3 Recent developments 365 14.1.17.3.1 Deals 365 14.2 OTHER PLAYERS 366 14.2.1 ONESOURCE PHARMA SOLUTIONS 366 14.2.2 RECIPHARM AB 366 14.2.3 EMERGENT BIOSOLUTIONS 367 14.2.4 SHANGHAI FOSUN PHARMACEUTICAL CO., LTD. 368 14.2.5 LOTTE BIOLOGICS 369 14.2.6 CURIA GLOBAL, INC. 369 14.2.7 POLYPLUS TRANSFECTION 370 14.2.8 ALDEVRON LLC 370 14.2.9 MINAPHARM PHARMACEUTICALS 370 14.2.10 RENTSCHLER BIOPHARMA SE 372 14.2.11 PORTON PHARMA SOLUTIONS 373 14.2.12 CELLARES, INC. 373 14.2.13 MABPLEX INTERNATIONAL CO., LTD. 374 14.2.14 ASYMCHEM INC. 374   15 APPENDIX 375 15.1 DISCUSSION GUIDE 375 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 378 15.3 CUSTOMIZATION OPTIONS 380 15.4 RELATED REPORTS 381 15.5 AUTHOR DETAILS 382
圖表清單 List of Tables & Figures
TABLE 1 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: INCLUSIONS & EXCLUSIONS 36 TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 49 TABLE 3 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: RISK ANALYSIS 51 TABLE 4 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 61 TABLE 5 LIST OF KEY BIOSIMILARS APPROVED, 2023–2025 62 TABLE 6 LIST OF EXPANSIONS BY TOP COMPANIES 67 TABLE 7 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ROLE IN ECOSYSTEM 75 TABLE 8 NUMBER OF PATENTS FILED IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2014–2024 77 TABLE 9 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: INDICATIVE LIST OF PATENTS, 2022 79 TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79 TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80 TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81 TABLE 13 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81 TABLE 14 COUNTRY-WISE REGULATORY SCENARIO FOR CONTRACT MANUFACTURING 82 TABLE 15 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2025–2026) 85 TABLE 16 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS 86 TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOPHARMACEUTICAL CONTRACT MANUFACTURING SERVICES (%) 88 TABLE 18 KEY BUYING CRITERIA FOR BIOPHARMACEUTICAL CONTRACT MANUFACTURING SERVICES, BY END USER 89 TABLE 19 US-ADJUSTED RECIPROCAL TARIFF RATES 93 TABLE 20 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 98 TABLE 21 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD MILLION) 99 TABLE 22 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 100 TABLE 23 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 100 TABLE 24 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 101 TABLE 25 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 101 TABLE 26 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD MILLION) 102 TABLE 27 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FORMULATION & FILL-FINISH SERVICES, BY REGION, 2023–2030 (USD MILLION) 103 TABLE 28 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FORMULATION & FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 29 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FORMULATION & FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 30 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FORMULATION & FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 31 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FORMULATION & FILL-FINISH SERVICES BY COUNTRY, 2023–2030 (USD MILLION) 105 TABLE 32 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FORMULATION & FILL-FINISH SERVICES, BY REGION, 2023–2030 (USD MILLION) 105 TABLE 33 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY REGION, 2023–2030 (USD MILLION) 106 TABLE 34 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 106 TABLE 35 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 36 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 37 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 38 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY REGION, 2023–2030 (USD MILLION) 108 TABLE 39 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY REGION, 2023–2030 (USD MILLION) 109 TABLE 40 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 41 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 42 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 43 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 44 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY REGION, 2023–2030 (USD MILLION) 111 TABLE 45 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 113 TABLE 46 BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY REGION, 2023–2030 (USD MILLION) 114 TABLE 47 NORTH AMERICA: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 48 EUROPE: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 49 ASIA PACIFIC: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 50 LATIN AMERICA: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 51 MIDDLE EAST: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY REGION, 2023–2030 (USD MILLION) 117 TABLE 52 BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY REGION, 2023–2030 (USD MILLION) 118 TABLE 53 NORTH AMERICA: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 54 EUROPE: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 55 ASIA PACIFIC: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 56 LATIN AMERICA: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 57 MIDDLE EAST: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY REGION, 2023–2030 (USD MILLION) 120 TABLE 58 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 122 TABLE 59 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2023–2030 (USD MILLION) 124 TABLE 60 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 61 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 62 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 63 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 64 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2023–2030 (USD MILLION) 126 TABLE 65 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2023–2030 (USD MILLION) 127 TABLE 66 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 67 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 68 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 69 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 70 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2023–2030 (USD MILLION) 129 TABLE 71 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 131 TABLE 72 TYPES OF MAMMALIAN EXPRESSION SYSTEMS 132 TABLE 73 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD MILLION) 132 TABLE 74 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 75 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 76 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 77 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 78 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD MILLION) 135 TABLE 79 TYPES OF MICROBIAL EXPRESSION SYSTEMS AND THEIR APPLICATIONS 135 TABLE 80 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD MILLION) 137 TABLE 81 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 82 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 83 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 84 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 85 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD MILLION) 139 TABLE 86 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 141 TABLE 87 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION) 142 TABLE 88 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 89 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 90 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 91 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 92 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION) 144 TABLE 93 FDA-APPROVED CAR T-CELL THERAPIES 145 TABLE 94 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY REGION, 2023–2030 (USD MILLION) 145 TABLE 95 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 96 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 97 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 98 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 99 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY REGION, 2023–2030 (USD MILLION) 148 TABLE 100 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY REGION, 2023–2030 (USD MILLION) 149 TABLE 101 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 102 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 103 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 104 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 105 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY REGION, 2023–2030 (USD MILLION) 151 TABLE 106 NIH FUNDING FOR VACCINE RESEARCH, 2018–2024 (USD MILLION) 152 TABLE 107 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY REGION, 2023–2030 (USD MILLION) 152 TABLE 108 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 109 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 110 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 111 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 112 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY REGION, 2023–2030 (USD MILLION) 155 TABLE 113 EXAMPLES OF PEPTIDE THERAPEUTICS 156 TABLE 114 COMMERCIALIZED RECOMBINANT PROTEINS USED IN MEDICINE 156 TABLE 115 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY REGION, 2023–2030 (USD MILLION) 157 TABLE 116 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 117 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 118 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 119 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 120 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY REGION, 2023–2030 (USD MILLION) 159 TABLE 121 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULES, BY REGION, 2023–2030 (USD MILLION) 160 TABLE 122 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 123 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 124 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 125 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 126 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULES, BY REGION, 2023–2030 (USD MILLION) 162 TABLE 127 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 164 TABLE 128 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION) 166 TABLE 129 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 130 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 131 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 132 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 133 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION) 168 TABLE 134 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2023–2030 (USD MILLION) 169 TABLE 135 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 136 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 137 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 138 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 139 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2023–2030 (USD MILLION) 171 TABLE 140 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION) 172 TABLE 141 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 142 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 143 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 144 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 145 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION) 174 TABLE 146 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY REGION, 2023–2030 (USD MILLION) 175 TABLE 147 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 148 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 149 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 150 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 151 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY REGION, 2023–2030 (USD MILLION) 178 TABLE 152 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION) 179 TABLE 153 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 154 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 155 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 156 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 181 TABLE 157 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION) 181 TABLE 158 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY REGION, 2023–2030 (USD MILLION) 182 TABLE 159 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 160 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 161 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 162 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 184 TABLE 163 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY REGION 2023–2030 (USD MILLION) 184 TABLE 164 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION) 185 TABLE 165 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 166 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 186 TABLE 167 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 186 TABLE 168 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 187 TABLE 169 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION) 187 TABLE 170 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION, 2023–2030 (USD MILLION) 189 TABLE 171 NORTH AMERICA: KEY MACROINDICATORS 192 TABLE 172 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 192 TABLE 173 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 193 TABLE 174 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 193 TABLE 175 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 194 TABLE 176 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 194 TABLE 177 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 195 TABLE 178 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 195 TABLE 179 US: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 196 TABLE 180 US: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 197 TABLE 181 US: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 197 TABLE 182 US: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 197 TABLE 183 US: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 198 TABLE 184 US: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 198 TABLE 185 CANADA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 199 TABLE 186 CANADA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 200 TABLE 187 CANADA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 200 TABLE 188 CANADA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 200 TABLE 189 CANADA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 201 TABLE 190 CANADA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 201 TABLE 191 EUROPE: KEY MACROINDICATORS 203 TABLE 192 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 203 TABLE 193 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 204 TABLE 194 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 204 TABLE 195 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 205 TABLE 196 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 205 TABLE 197 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 206 TABLE 198 EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 206 TABLE 199 GERMANY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 207 TABLE 200 GERMANY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 208 TABLE 201 GERMANY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 208 TABLE 202 GERMANY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 208 TABLE 203 GERMANY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 209 TABLE 204 GERMANY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 209 TABLE 205 UK: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 210 TABLE 206 UK: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 211 TABLE 207 UK: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 211 TABLE 208 UK: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 211 TABLE 209 UK: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 212 TABLE 210 UK: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 212 TABLE 211 FRANCE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 213 TABLE 212 FRANCE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 214 TABLE 213 FRANCE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 214 TABLE 214 FRANCE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 214 TABLE 215 FRANCE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 215 TABLE 216 FRANCE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 215 TABLE 217 ITALY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 216 TABLE 218 ITALY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 217 TABLE 219 ITALY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 217 TABLE 220 ITALY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 217 TABLE 221 ITALY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 218 TABLE 222 ITALY: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 218 TABLE 223 SPAIN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 219 TABLE 224 SPAIN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 220 TABLE 225 SPAIN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 220 TABLE 226 SPAIN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 220 TABLE 227 SPAIN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 221 TABLE 228 SPAIN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 221 TABLE 229 SWITZERLAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 222 TABLE 230 SWITZERLAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 222 TABLE 231 SWITZERLAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 223 TABLE 232 SWITZERLAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 223 TABLE 233 SWITZERLAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 224 TABLE 234 SWITZERLAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 224 TABLE 235 IRELAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 225 TABLE 236 IRELAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 225 TABLE 237 IRELAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 226 TABLE 238 IRELAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 226 TABLE 239 IRELAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 227 TABLE 240 IRELAND: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 227 TABLE 241 REST OF EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 228 TABLE 242 REST OF EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 228 TABLE 243 REST OF EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 229 TABLE 244 REST OF EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 229 TABLE 245 REST OF EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 230 TABLE 246 REST OF EUROPE: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 230 TABLE 247 ASIA PACIFIC: KEY MACROINDICATORS 233 TABLE 248 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 233 TABLE 249 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 234 TABLE 250 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 234 TABLE 251 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 235 TABLE 252 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 235 TABLE 253 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 236 TABLE 254 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 236 TABLE 255 CHINA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 238 TABLE 256 CHINA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 238 TABLE 257 CHINA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 239 TABLE 258 CHINA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 239 TABLE 259 CHINA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 240 TABLE 260 CHINA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 240 TABLE 261 JAPAN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 241 TABLE 262 JAPAN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 242 TABLE 263 JAPAN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 242 TABLE 264 JAPAN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 242 TABLE 265 JAPAN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 243 TABLE 266 JAPAN: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 243 TABLE 267 INDIA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 244 TABLE 268 INDIA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 245 TABLE 269 INDIA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 245 TABLE 270 INDIA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 245 TABLE 271 INDIA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 246 TABLE 272 INDIA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 246 TABLE 273 SOUTH KOREA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 247 TABLE 274 SOUTH KOREA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 248 TABLE 275 SOUTH KOREA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 248 TABLE 276 SOUTH KOREA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 248 TABLE 277 SOUTH KOREA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 249 TABLE 278 SOUTH KOREA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 249 TABLE 279 REST OF ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 250 TABLE 280 REST OF ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 251 TABLE 281 REST OF ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 251 TABLE 282 REST OF ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 251 TABLE 283 REST OF ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 252 TABLE 284 REST OF ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 252 TABLE 285 LATIN AMERICA: KEY MACROINDICATORS 254 TABLE 286 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 254 TABLE 287 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 255 TABLE 288 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 255 TABLE 289 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 256 TABLE 290 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 256 TABLE 291 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 257 TABLE 292 LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 257 TABLE 293 BRAZIL: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 258 TABLE 294 BRAZIL: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 258 TABLE 295 BRAZIL: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 259 TABLE 296 BRAZIL: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 259 TABLE 297 BRAZIL: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 260 TABLE 298 BRAZIL: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 260 TABLE 299 MEXICO: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 261 TABLE 300 MEXICO: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 261 TABLE 301 MEXICO: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 262 TABLE 302 MEXICO: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 262 TABLE 303 MEXICO: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 263 TABLE 304 MEXICO: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 263 TABLE 305 REST OF LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 264 TABLE 306 REST OF LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 264 TABLE 307 REST OF LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 265 TABLE 308 REST OF LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 265 TABLE 309 REST OF LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 266 TABLE 310 REST OF LATIN AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 266 TABLE 311 MIDDLE EAST: KEY MACROINDICATORS 268 TABLE 312 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION, 2023–2030 (USD MILLION) 268 TABLE 313 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 268 TABLE 314 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 269 TABLE 315 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 269 TABLE 316 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 269 TABLE 317 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 270 TABLE 318 MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 270 TABLE 319 GCC COUNTRIES: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 271 TABLE 320 GCC COUNTRIES: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 272 TABLE 321 GCC COUNTRIES: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 272 TABLE 322 GCC COUNTRIES: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 273 TABLE 323 GCC COUNTRIES: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 273 TABLE 324 GCC COUNTRIES: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 274 TABLE 325 REST OF MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 275 TABLE 326 REST OF MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 275 TABLE 327 REST OF MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 276 TABLE 328 REST OF MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 276 TABLE 329 REST OF MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 277 TABLE 330 REST OF MIDDLE EAST: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 277 TABLE 331 AFRICA: KEY MACROINDICATORS 279 TABLE 332 AFRICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023–2030 (USD MILLION) 279 TABLE 333 AFRICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2023–2030 (USD MILLION) 280 TABLE 334 AFRICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION) 280 TABLE 335 AFRICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023–2030 (USD MILLION) 281 TABLE 336 AFRICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023–2030 (USD MILLION) 281 TABLE 337 AFRICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 282 TABLE 338 STRATEGIES DEPLOYED BY KEY PLAYERS 283 TABLE 339 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DEGREE OF COMPETITION 287 TABLE 340 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: REGION FOOTPRINT 292 TABLE 341 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SERVICE TYPE FOOTPRINT 293 TABLE 342 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: MOLECULE TYPE FOOTPRINT 294 TABLE 343 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: THERAPEUTIC AREA FOOTPRINT 295 TABLE 344 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DETAILED LIST OF KEY SMES/STARTUPS 298 TABLE 345 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, 2024 299 TABLE 346 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SERVICE LAUNCHES, JANUARY 2022–JUNE 2025 302 TABLE 347 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DEALS, JANUARY 2022–JUNE 2025 302 TABLE 348 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: EXPANSIONS, JANUARY 2022– JUNE 2025 303 TABLE 349 LONZA: COMPANY OVERVIEW 304 TABLE 350 LONZA: SERVICES OFFERED 306 TABLE 351 LONZA: DEALS, JANUARY 2022–JUNE 2025 307 TABLE 352 LONZA: EXPANSIONS, JANUARY 2022–JUNE 2025 308 TABLE 353 WUXI BIOLOGICS: COMPANY OVERVIEW 309 TABLE 354 WUXI BIOLOGICS: SERVICES OFFERED 311 TABLE 355 WUXI BIOLOGICS: DEALS, JANUARY 2022–JUNE 2025 312 TABLE 356 WUXI BIOLOGICS: EXPANSIONS, JANUARY 2022– JUNE 2025 312 TABLE 357 SAMSUNG BIOLOGICS: COMPANY OVERVIEW 314 TABLE 358 SAMSUNG BIOLOGICS: SERVICES OFFERED 316 TABLE 359 SAMSUNG BIOLOGICS: SERVICE LAUNCHES, JANUARY 2022–JUNE 2025 316 TABLE 360 SAMSUNG BIOLOGICS: DEALS, JANUARY 2022–JUNE 2025 316 TABLE 361 SAMSUNG BIOLOGICS: EXPANSIONS, JANUARY 2022–JUNE 2025 317 TABLE 362 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 319 TABLE 363 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED 321 TABLE 364 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–JUNE 2025 321 TABLE 365 ABBVIE INC.: COMPANY OVERVIEW 323 TABLE 366 ABBVIE INC.: SERVICES OFFERED 324 TABLE 367 CATALENT, INC.: COMPANY OVERVIEW 325 TABLE 368 CATALENT, INC.: SERVICES OFFERED 326 TABLE 369 CATALENT, INC.: DEALS, JANUARY 2022–JUNE 2025 328 TABLE 370 CATALENT, INC.: EXPANSIONS, JANUARY 2022–JUNE 2025 328 TABLE 371 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW 330 TABLE 372 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SERVICES OFFERED 332 TABLE 373 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2025 333 TABLE 374 FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW 334 TABLE 375 FUJIFILM HOLDINGS CORPORATION: SERVICES OFFERED 335 TABLE 376 FUJIFILM HOLDINGS CORPORATION: DEALS, JANUARY 2022–JUNE 2025 336 TABLE 377 FUJIFILM HOLDINGS CORPORATION: EXPANSIONS, JANUARY 2022–JUNE 2025 337 TABLE 378 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 338 TABLE 379 EUROFINS SCIENTIFIC: SERVICES OFFERED 340 TABLE 380 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2022–JUNE 2025 340 TABLE 381 GENSCRIPT BIOTECH CORPORATION: COMPANY OVERVIEW 342 TABLE 382 GENSCRIPT BIOTECH CORPORATION: SERVICES OFFERED 344 TABLE 383 GENSCRIPT BIOTECH CORPORATION: SERVICE LAUNCHES, JANUARY 2022–JUNE 2025 344 TABLE 384 GENSCRIPT BIOTECH CORPORATION: DEALS, JANUARY 2022–JUNE 2025 345 TABLE 385 GENSCRIPT BIOTECH CORPORATION: EXPANSIONS, JANUARY 2022–JUNE 2025 345 TABLE 386 ACG INC.: COMPANY OVERVIEW 346 TABLE 387 AGC INC.: SERVICES OFFERED 347 TABLE 388 AGC INC: DEALS, JANUARY 2022–JUNE 2025 348 TABLE 389 AGC INC.: EXPANSIONS, JANUARY 2022–JUNE 2025 349 TABLE 390 MERCK KGAA: COMPANY OVERVIEW 350 TABLE 391 MERCK KGAA: SERVICES OFFERED 351 TABLE 392 MERCK KGAA: DEALS, JANUARY 2022–JUNE 2025 352 TABLE 393 MERCK KGAA: EXPANSIONS, JANUARY 2022–JUNE 2025 352 TABLE 394 JSR CORPORATION: COMPANY OVERVIEW 353 TABLE 395 JSR CORPORATION: SERVICES OFFERED 355 TABLE 396 JSR CORPORATION: EXPANSIONS, JANUARY 2022–JUNE 2025 355 TABLE 397 IDT BIOLOGIKA: COMPANY OVERVIEW 356 TABLE 398 IDT BIOLOGIKA: SERVICES OFFERED 356 TABLE 399 IDT BIOLOGIKA: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2025 357 TABLE 400 AJINOMOTO BIO-PHARMA: COMPANY OVERVIEW 358 TABLE 401 AJINOMOTO BIO-PHARMA: SERVICES OFFERED 359 TABLE 402 AJINOMOTO BIO-PHARMA: DEALS, JANUARY 2022–JUNE 2025 359 TABLE 403 AGILENT TECHNOLOGIES INC.: COMPANY OVERVIEW 360 TABLE 404 AGILENT TECHNOLOGIES INC.: SERVICES OFFERED 361 TABLE 405 AGILENT TECHNOLOGIES INC.: DEALS, JANUARY 2022–JUNE 2025 362 TABLE 406 ASAHI KASEI CORPORATION: COMPANY OVERVIEW 363 TABLE 407 ASAHI KASEI CORPORATION: SERVICES OFFERED 364 TABLE 408 ASAHI KASEI CORPORATION: DEALS, JANUARY 2022–JUNE 2025 365 TABLE 409 ONESOURCE PHARMA SOLUTIONS: COMPANY OVERVIEW 366 TABLE 410 RECIPHARM AB: COMPANY OVERVIEW 366 TABLE 411 EMERGENT: COMPANY OVERVIEW 367 TABLE 412 SHANGHAI FOSUN PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW 368 TABLE 413 LOTTE BIOLOGICS: COMPANY OVERVIEW 369 TABLE 414 CURIA GLOBAL, INC.: COMPANY OVERVIEW 369 TABLE 415 POLYPLUS TRANSFECTION: COMPANY OVERVIEW 370 TABLE 416 ALDEVRON LLC: COMPANY OVERVIEW 370 TABLE 417 MINAPHARM PHARMACEUTICALS: COMPANY OVERVIEW 370 TABLE 418 RENTSCHLER BIOPHARMA SE: COMPANY OVERVIEW 372 TABLE 419 PORTON PHARMA SOLUTIONS: COMPANY OVERVIEW 373 TABLE 420 CELLARES, INC.: COMPANY OVERVIEW 373 TABLE 421 MABPLEX INTERNATIONAL CO., LTD.: COMPANY OVERVIEW 374 TABLE 422 ASYMCHEM INC.: COMPANY OVERVIEW 374 FIGURE 1 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SEGMENTATION & REGIONAL SCOPE 35 FIGURE 2 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: YEARS CONSIDERED 37 FIGURE 3 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: RESEARCH DESIGN 39 FIGURE 4 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: KEY DATA FROM SECONDARY SOURCES 41 FIGURE 5 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 42 FIGURE 6 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 43 FIGURE 7 COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH (2024) 44 FIGURE 8 REVENUE SHARE ANALYSIS OF THERMO FISHER SCIENTIFIC INC. (2024) 44 FIGURE 9 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE VALIDATION FROM PRIMARY SOURCES 46 FIGURE 10 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: TOP-DOWN APPROACH 47 FIGURE 11 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: CAGR PROJECTIONS 48 FIGURE 12 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DATA TRIANGULATION 50 FIGURE 13 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2025 VS. 2030 (USD MILLION) 52 FIGURE 14 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION) 53 FIGURE 15 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SOURCE, 2025 VS. 2030 (USD MILLION) 53 FIGURE 16 GEOGRAPHICAL SNAPSHOT OF BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET 54 FIGURE 17 INCREASING APPROVALS OF BIOLOGICS TO DRIVE MARKET GROWTH DURING FORECAST PERIOD 56 FIGURE 18 COMMERCIAL OPERATIONS SEGMENT TO ACCOUNT FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2025 57 FIGURE 19 ONCOLOGY SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2030 57 FIGURE 20 MONOCLONAL ANTIBODIES TO CONTINUE TO DOMINATE MARKET IN 2030 58 FIGURE 21 ASIA PACIFIC TO BE FASTEST-GROWING MARKET IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET DURING FORECAST PERIOD 59 FIGURE 22 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60 FIGURE 23 PERSONALIZED MEDICINES (% OF ALL FDA-APPROVED DRUGS), 2015–2024 65 FIGURE 24 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 72 FIGURE 25 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: VALUE CHAIN ANALYSIS 74 FIGURE 26 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ECOSYSTEM MAP 75 FIGURE 27 PATENT ANALYSIS OF BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, JANUARY 2014–DECEMBER 2024 78 FIGURE 28 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS 86 FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOPHARMACEUTICAL CONTRACT MANUFACTURING SERVICES 88 FIGURE 30 KEY BUYING CRITERIA FOR BIOPHARMACEUTICAL CONTRACT MANUFACTURING SERVICES, BY END USER 89 FIGURE 31 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: INVESTMENT & FUNDING SCENARIO 90 FIGURE 32 NORTH AMERICA: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SNAPSHOT 191 FIGURE 33 ASIA PACIFIC: BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET SNAPSHOT 232 FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2020–2024 (USD MILLION) 285 FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET (2024) 287 FIGURE 36 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 290 FIGURE 37 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY FOOTPRINT 291 FIGURE 38 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX (SMES/STARTUPS), 2024 297 FIGURE 39 EV/EBITDA OF KEY VENDORS 300 FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 300 FIGURE 41 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 301 FIGURE 42 LONZA: COMPANY SNAPSHOT (2024) 305 FIGURE 43 WUXI BIOLOGICS: COMPANY SNAPSHOT (2024) 310 FIGURE 44 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2024) 315 FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 320 FIGURE 46 ABBVIE INC.: COMPANY SNAPSHOT (2024) 324 FIGURE 47 CATALENT, INC.: COMPANY SNAPSHOT (2024) 326 FIGURE 48 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2024) 331 FIGURE 49 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2024) 335 FIGURE 50 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024) 339 FIGURE 51 SGENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2024) 343 FIGURE 52 AGC INC.: COMPANY SNAPSHOT (2024) 347 FIGURE 53 MERCK KGAA: COMPANY SNAPSHOT (2024) 351 FIGURE 54 JSR CORPORATION: COMPANY SNAPSHOT (2024) 354 FIGURE 55 AJINOMOTO BIO-PHARMA: COMPANY SNAPSHOT (2024) 359 FIGURE 56 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2024) 361 FIGURE 57 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2024) 364

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們